World's Best Scientists 2026 revealed!
George E. Peoples

George E. Peoples

D-Index & Metrics

Biology and Biochemistry

D-Index
53
Citations
8697
World Ranking
16309
National Ranking
6752

George E. Peoples publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where George E. Peoples sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 297 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

George E. Peoples D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where George E. Peoples sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 53 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

George E. Peoples is affiliated with LumaBridge in the United States, focusing on research primarily within medicine, immunology, and molecular biology. Their work extensively covers oncology, immunology, radiology, molecular biology, and biotechnology subfields.

Their research intersects multiple topics including immunotherapy and immune responses, monoclonal and polyclonal antibodies research, cancer immunotherapy and biomarkers, vaccines and immunoinformatics approaches, CAR-T cell therapy research, cancer research and treatments, and HER2/EGFR in cancer research.

Frequent co-authors collaborating with George E. Peoples include Guy T. Clifton, Timothy J. Vreeland, Robert C. Chick, Diane F. Hale, and Anne E. O'Shea.

Their publications have appeared notably in these venues:

  • Cancer Research
  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Annals of Surgical Oncology
  • HPB

Recent papers authored or co-authored by George E. Peoples cover clinical trials and cancer immunotherapy, including:

  • Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer (2020, Clinical Cancer Research)
  • Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence (2020, Breast Cancer Research and Treatment)
  • Chemoprevention in familial adenomatous polyposis: past, present and future (2020, Familial Cancer)
  • Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer (2021, Clinical Immunology)
  • A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis (2021, Annals of Surgical Oncology)

Best Publications

  • T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells.

    Srully Blotnick;George E. Peoples;Michael R. Freeman;Timothy J. Eberlein

  • Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

    Elizabeth Ann Mittendorf;G. T. Clifton;J. P. Holmes;E. Schneble

  • Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients

    George E. Peoples;Jennifer M. Gurney;Matthew T. Hueman;Mike M. Woll

  • Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

    George E. Peoples;George E. Peoples;Jarrod P. Holmes;Jarrod P. Holmes;Matthew T. Hueman;Matthew T. Hueman;Elizabeth A. Mittendorf

  • Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

    Elizabeth Ann Mittendorf;Guy T. Clifton;Jarrod P. Holmes;Kevin S. Clive

  • T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role.

    George E. Peoples;Srully Blotnick;Kazue Takahashi;Michael R. Freeman

  • Extracorporeal shock wave therapy suppresses the early proinflammatory immune response to a severe cutaneous burn injury.

    Thomas A Davis;Alexander Stojadinovic;Khairul Anam;Mihret Amare

  • Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial

    Elizabeth A. Mittendorf;Biao Lu;Michelle Melisko;Julie Price Hiller

  • The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

    Linda C. Benavides;Jeremy D. Gates;Mark G. Carmichael;Ritesh Patel

  • Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine

    Jarrod P. Holmes;Linda C. Benavides;Jeremy D. Gates;Mark G. Carmichael

  • Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

    Victor A Gall;Anne V Philips;Na Qiao;Karen Clise-Dwyer

  • The E75 HER2/ neu peptide vaccine

    Elizabeth A. Mittendorf;Jarrod P. Holmes;Jarrod P. Holmes;Sathibalan Ponniah;George E. Peoples;George E. Peoples

  • Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.

    Mark G. Carmichael;Linda C. Benavides;Jarrod P. Holmes;Jeremy D. Gates

  • Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer

    Elizabeth Ann Mittendorf;Catherine E. Storrer;Craig D. Shriver;Sathibalan Ponniah

  • Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex® technology

    Zia A. Dehqanzada;Catherine E. Storrer;Matthew T. Hueman;Rebecca J. Foley

  • Prospective randomized study comparing sentinel lymph node evaluation with standard pathologic evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI-01.

    Alexander Stojadinovic;Aviram Nissan;Mladjan Protic;Carol F. Adair

  • Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer.

    Alexander R. Miller;Scott B. Cantor;George E. Peoples;David B. Pearlstone

  • Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence

    Elizabeth A. Mittendorf;Alexandros Ardavanis;Jennifer K. Litton;Nathan M. Shumway

  • Vaccine Implications of Folate Binding Protein, a Novel Cytotoxic T Lymphocyte-recognized Antigen System in Epithelial Cancers

    George E. Peoples;George E. Peoples;George E. Peoples;Brett W. Anderson;Tom V. Lee;James L. Murray

  • Primary Analysis of a Prospective, Randomized, Single-Blinded Phase II Trial Evaluating the HER2 Peptide AE37 Vaccine in Breast Cancer Patients to Prevent Recurrence

    E. A. Mittendorf;A. Ardavanis;J. Symanowski;J. L. Murray

Frequent Co-Authors

Elizabeth A. Mittendorf
Elizabeth A. Mittendorf Brigham and Women's Hospital
Alexander Stojadinovic
Alexander Stojadinovic Uniformed Services University of the Health Sciences
Michael Papamichail
Michael Papamichail St Savas Hospital
David G. McLeod
David G. McLeod Uniformed Services University of the Health Sciences
Constantin N. Baxevanis
Constantin N. Baxevanis St Savas Hospital
David M. Gershenson
David M. Gershenson The University of Texas MD Anderson Cancer Center
Kelly K. Hunt
Kelly K. Hunt The University of Texas MD Anderson Cancer Center
S. Eva Singletary
S. Eva Singletary The University of Texas MD Anderson Cancer Center
Judd W. Moul
Judd W. Moul Duke University
Henry Mark Kuerer
Henry Mark Kuerer The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're exploring majors like Biology or Biochemistry, a variety of online degree pathways can help tailor your education and career goals. Many students start with a biology degree online, enabling flexible study while building a foundation in the life sciences. This path is ideal for those considering lab work, research, or advanced degrees.

Healthcare roles continue to be in high demand. Pursuing online associate rn programs offers a fast and practical entry into nursing—making it possible to gain clinical skills and credentials while balancing work or family obligations.

Nutrition and wellness are also fast-growing fields. Those interested in dietetics or community health might consider online nutrition degrees, which blend biology, biochemistry, and applied health science into versatile career options.

If leadership in healthcare appeals to you, top cahme accredited mha programs prepare graduates for management roles within hospitals, public health organizations, and biotech companies. Combining advanced science knowledge with administrative skills can open up broader long-term career prospects.

Best Scientists Citing George E. Peoples

Trending Scientists

Recently Published Articles